Reported 10 months ago
Eli Lilly is experiencing growth, but Vertex Pharmaceuticals offers more opportunities. Vertex, despite being smaller, boasts a market cap of over $120 billion and is outperforming the S&P 500. With a focus on rare diseases like cystic fibrosis and potential new therapies, Vertex presents a strong investment choice over Eli Lilly. Additionally, Vertex's lower valuation compared to Lilly makes it a more attractive pick for investors.
Source: YAHOO